NAS:ICPT (USA) Also Trade In: Germany Mexico

Intercept Pharmaceuticals Inc $ 35.91 -0.7 (-1.91%)

Avg Vol (1m):
Market Cap $:
1.18 Bil
Enterprise Value $:
1.25 Bil
P/E (TTM):
Warning! GuruFocus has detected 3 Severe warning signs with ICPT. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 10Y (-%)

Intercept Pharmaceuticals Inc News and Headlines -

GuruFocus Articles Total 21
  • 1
  • 2

The company needs to get liver disease drug approved and find help to commercialize it

The risk of investing in Viking Therapeutics Inc. (VKTX) may not be worth the potential rewards, according to a December article in Equities News. Investors who failed to heed this warning and bought shares of the San Diego-based biotechnology company haven’t been helped, but they haven’t been hurt either.

That’s because Viking is trading just about where it was in mid-December: $7.50. The company has made a nice recovery from mid-March, when it traded at a 52-week low of $3.26.

Viking’s future is closely tied to the success of one of only three drugs in its pipeline, VK2809. The company

149 Views    Barry Cohen    2020-06-15 20:19
Company's high hopes for NASH drug stymied, providing opening for Intercept Pharma treatment

Genfit’s (GNFT) loss may be a gain for other companies developing a treatment for one of the most rapidly growing health problems around the world, particularly Intercept Pharmaceuticals Inc. (ICPT).

Shares of Lille, France-based Genfit plunged about 70% this week as the company reported that in a phase 3 trial, its drug to treat nonalcoholic steatohepatitis failed to meet study goals. The company said it would work with regulators to determine the next steps regarding continuation of the trial, according to an article in Feedspot.

Genfit’s elafibranor was one of the two most highly touted NASH drugs. Now moving to

232 Views    Barry Cohen    2020-05-14 20:31
Intercept Pharmaceuticals hoping for approval on medication to compete in large and fast-growing market for NASH treatments

The U.S. Food and Drug Administration is scheduled to make decisions on five therapies in the second quarter, and the one that could make the biggest impact on the company and its shares belongs to Intercept Pharmaceuticals Inc. (ICPT).

The New York-based biotech could certainly use a boost. At just over $65, the stock is off about 50% from its 52-week high. TipRanks reported that the 13 analysts following Intercept rated it a strong buy with a target price of $151, but those estimates appear to be pre-coronavirus so investors should view them skeptically.

Intercept is hoping the

288 Views    Barry Cohen    2020-03-30 21:06
Despite potentially being the first NASH drug approved by the FDA, Intercept's obeticholic acid faces several roadblocks

It has now been six years since Intercept Pharmaceuticals (ICPT) brought non-alcoholic steatohepatitis (NASH) to the forefront of biotech paradigm shifts. Back in November 2014, the stock exploded to all time highs on the back of positive data for a mid phase NASH trial.

The stock has steadily fallen ever since, but 2020 could prove to be the year when flagship NASH drug obeticholic acid (OCA) gains FDA approval. OCA will be up for review in April by an FDA advisory committee, followed closely by the agency’s decision on approval.

OCA isn’t perfect, but the very high prevalence of NASH,

128 Views    Matt Winkler    2019-12-24 16:05
French biopharmaceutical company hopes to become first to get approval of treatment for liver disorder that affects up to 30 million Americans

A French biopharmaceutical company hopes to become the first to gain approval of a drug to treat a widespread liver disease. If Genfit SA (GNFT) is successful, the payoff promises to be huge—for the company and its investors. But there are many big “ifs.”

The disease Genfit is targeting is nonalcoholic steatohepatitis, a progressive liver disorder caused by an immune system that attacks fatty liver tissue. It is estimated that the disease affects some 30 million Americans. The market opportunity is estimated by analysts to be up to $35 billion, according to an article in Forbes earlier this

236 Views    Barry Cohen    2019-12-10 20:36
PTC Therapeutics makes the list

According to the GuruFocus All-In-One Screener, the following health care stocks are popular among gurus.

Integer Holdings Corp. (ITGR) is held by nine gurus

The medical devices and components manufacturer has a market cap of $2.66 billion. Its revenue of $1.23 billion has grown 5.40% over a 10-year period.

The stock is trading with a price-earnings ratio of 14.60. The share price of $81.8 is 11.29% below the 52-week high and 24.10% above the 52-week low. Over the last 10 years, it has returned 325%.

The company’s largest shareholder among the gurus is Ken Fisher (Trades,

160 Views    Tiziano Frateschi    2019-07-10 20:41
Details the CEO buys this past week from the following companies: OPKO Health, Intercept Pharmaceuticals, New Media Investment Group, Macy's and Aclaris Therapeutics

According to GuruFocus Insider Data, these are the largest CEO buys during the past week.

OPKO Health CEO bought 294,527 shares

OPKO Health Inc. (OPK) CEO, Chairman and 10% Owner Phillip Frost bought 294,527 shares during the week at an average price of $3.06.

The diversified health care company, whose business includes diagnostics and provision of pharmaceutical products, has a market cap of $1.67 billion. Its shares traded around $2.99 on Friday.

Consolidated revenue for the quarter ended Dec. 31 was $193.7 million, compared to $275.5 million in the prior-year period.

Frost bought 60,000 shares on April 6 at a

47 Views    Joy Hu    2018-04-16 14:28
Intercept Pharmaceuticals, Cloudera, OPKO Health and Entercom Communications among top buys

The largest Insider Buys this week were for Intercept Pharmaceuticals Inc. (ICPT), Cloudera Inc. (CLDR), OPKO Health Inc. (OPK) and Entercom Communications Corp. (ETM).

Intercept Pharmaceuticals director bought 7,812 shares

Director Daniel Bradbury bought 7,812 shares of Intercept stock on April 9 at the average price of $64 per share. The stock price has increased by 14.17% since then.

Intercept Pharmaceuticals is a biopharmaceutical company that focuses on the development of novel synthetic bile acid analogs to treat chronic liver diseases. The company focuses on diseases such as primary biliary cirrhosis and primary sclerosing cholangitis. The company has a market

332 Views    Shuda Xia    2018-04-14 13:23

On May 19, Intercept Pharmaceuticals Inc (ICPT) announced plans for an international Phase 3 trial of OCA in patients with NASH. Although this announcement should have boosted the stock, shares slid 10% in after-hours trading.

Some believe the stock fell because the endpoints agreed upon in the upcoming trial are slightly different than the endpoints used in Intercept’s previous study. Others believe the stock fell after CEO Mark Pruzanski and CMO David Shapiro unloaded a combined total over $2.7 million in shares, even though it was sold as an automatic transaction.

565 Views    TipRanks    2015-05-20 22:30

On May 11, Intercept Pharmaceuticals (ICPT) reported first quarter earnings for 2015. The biopharmaceutical company does not yet have any approved products in its portfolio but is working on gaining approval for its lead candidate, OCA.

Highlights from the company’s quarterly report included a net loss of $39.4 million, or a loss of $(1.78) per share. This is a wider loss than the analyst consensus of $(1.69) but an improvement from $(12.61) in the same quarter of last year. CFO Barbara Duncan reiterated Intercept’s adjusted operating expense guidance for full-year 2015 of $180 million to $200 million.

Intercept Pharmaceuticals

829 Views    TipRanks    2015-05-12 19:30

On April 6, analysts at Wedbush led by Liana Moussatos highlighted upcoming events in the biotech sector. Here is what to watch for:

OvaScience Inc (OVAS): In mid-April, OvaScience anticipates the first live births from their AUGMENT technology.

Ovascience focuses on developing fertility treatments for women. AUGMENT, the company’s leading treatment, aims to bolster the health of a woman’s eggs as she undergoes in vitro fertilization (IVF). AUGMENT was launched in certain IVF clinics last year but is not available in the United States. On March 26, OvaScience announced that AUGMENT produced positive trial results and improved

833 Views    TipRanks    2015-04-07 19:47

According to GuruFocus Insider Data, the largest insider sells during the past week were: Intercept Pharmaceuticals Inc (ICPT), Target Corp (TGT), Aetna Inc (AET) and Ross Stores Inc (ROST).

The overall trend of insiders is illustrated in the chart below:

Intercept Pharmaceuticals Inc (ICPT): Director Jonathan Silverstein sold 207,800 shares

Director Jonathan Silverstein sold 207,800 shares of ICPT stock on 03/25/2015 at the average price of $274.41. Silverstein owns at least 1,277,524 shares after this. The price of the stock has increased by 7.58% since.

Intercept Pharmaceuticals reported fourth-quarter net loss

946 Views    Jimmy Xiao    2015-03-30 21:46

According to GuruFocus Insider Data, the recent CFO sales were: Intercept Pharmaceuticals Inc. (ICPT), Ross Stores Inc. (ROST), and Sally Beauty Holdings Inc. (SBH).

Intercept Pharmaceuticals Inc. (ICPT): CFO Barbara Gayle Duncan sold 141 shares

On 01/05/2015, CFO Barbara Gayle Duncan sold 141 shares at an average price of $176.49. The price of the stock has increased by 66.53% since. Intercept Pharmaceuticals Inc. has a market cap of $6.65 billion, and its shares were traded at around $293.91. The company has a P/S ratio of 3507.70.

Intercept Pharmaceuticals Inc. announced its 2014 fourth-quarter results with revenues and gross profit

1278 Views    Myra Ramdenbourg    2015-03-30 14:06

By Carly Forster

Intercept Pharmaceuticals (ICPT) is a biopharmaceutical company known for developing drug treatments for chronic liver diseases. The company’s current leading drug is obeticholic acid (OCA). OCA is used to treat Primary Biliary Cirrhosis (PBC), portal hypertension, bile acid diarrhea, and nonalcoholic steatohepatitis (NASH).

On March 20, Intercept announced 2 new findings from subgroups in the Phase 2b FLINT trial of OCA in patients with NASH: efficacy in high-risk patients, and characterization of effects on cardio metabolic parameters.

The efficacy in high-risk patients’ sub-group monitored patients who had beginning to advanced stage of fibrosis, concomitant diabetes, obesity,

436 Views    TipRanks    2015-03-24 21:30

By Sarah Roden

Intercept Pharma (ICPT) released its fourth quarter and full year 2014’s financial results on March 2, 2015. The biopharmaceutical company focuses on chronic liver diseases, although it does not yet produce any drugs of its own. Intercept is in the process of gaining approval for obeticholic acid (OCA), but the company currently earns revenue through research partnerships.

The report revealed widened losses but posted revenue above expectations. Intercept posted fourth quarter net losses of -$1.63 a share, wider than the loss of -$0.64 from the same quarter of last year. Zack’s estimated a loss of -$1.53

323 Views    TipRanks    2015-03-03 22:10

Out of all of the stocks in the Healthcare sector, biopharmaceutical stocks are some of the most popular due to the revenue potential of discovering new treatments. The process between the discovery of a drug to potential FDA approval can determine whether a company’s stock will flop or prevail. On February 3, Wedbush analyst Liana Moussatos issued a note to investors naming the top catalysts for emerging pharmaceuticals in February and all of 2015. Highlights from her report are as follows:

Intercept Pharmaceuticals (NASDAQ: ICPT):

Intercept Pharmaceuticals (ICPT) is a biopharmaceutical company known for

410 Views    TipRanks    2015-02-04 18:43 Pharmaceuticals, Inc. (ICPT)

Shares of Intercept Pharmaceuticals (ICPT) skyrocketed more than 20% in after-hours trading on Thursday, following the announcement that the company's obeticholic acid (OCA) has received "breakthrough therapy designation" from the FDA for the treatment of patients with nonalcoholic steatohepatitis (NASH) with liver fibrosis

This designation, created by the U.S. Food and Drug Administration (FDA) to speed the availability of new therapies for serious or life-threatening conditions, will enable ICPT to work closely with the FDA to finalize the design of its Phase 3 program

NASH is a serious chronic liver disease caused by

526 Views    riddock57    2015-01-30 16:09

In this article, let´s see Steven Cohen (Trades, Portfolio)´s return, a guru who has a net worth of about $12 billion, and in a wealth ranking is situated in the place 19 in the industry and 43 in the U.S.; continues having impressive returns. He had generated average annual returns of 30%, on top of the hedge-fund industry, since SAC Capital launched in 1992.

SAC Capital

SAC Capital becomes Point72 Asset Management in April, because the hedge fund was accused of running insider trading. Eight money managers and analysts have pleaded guilty or been convicted of using

819 Views    Omar Venerio    2014-07-31 14:18

According to GuruFocus Insider Data, the recent CFO sales were: Intercept Pharmaceuticals Inc., Micron Technology Inc. and Facebook Inc.

Intercept Pharmaceuticals Inc. (ICPT): CFO Barbara Gayle Duncan Sold 5,625 Shares

On 01/15/2014, CFO Barabara Gayla Duncan sold 5,625 shares at an average price of $273.68. The price of the stock has decreased by 2.8% since. Intercept Pharmaceuticals Inc has a market cap of $5.19 billion and its shares were traded at around $266.01. The company has a P/S ratio of 3325.13.

Intercept Pharmaceuticals Inc announced their 2013 fourth quarter results with revenues and gross profit of $405 thousand; the

1569 Views    Myra Ramdenbourg    2014-04-14 13:54
Intercept Pharmaceuticals Inc. was incorporated in the State of Delaware on Sept. 4, 2002. Intercept Pharmaceuticals Inc. has a market cap of $931 million; its shares were traded at around $50.61 with and P/S ratio of 230.10. President and CEO of Intercept Pharmaceuticals Inc. (ICPT) Mark Pruzanski sold 37,500 shares on July 9, 2013 at an average price of $46.36. The total transaction amount was $1,738,500. Mark Pruzanski is the co-founder, president and CEO of Intercept Pharmaceuticals. He has been a member of the board of directors since the start of the company in 2002. Pruzanski has 15 years of
544 Views    alicet236    2013-07-11 21:01

Headlines Total 139
  • 1
  • 2

2020-12-02 $ 36.61 (2.58%)
2020-12-01 $ 35.69 (0.51%)
2020-11-26 $ 37.39 (%)
2020-11-24 $ 36.41 (2.65%)
2020-11-19 $ 37.36 (-2.76%)
2020-11-17 $ 37.55 (-0.84%)
2020-11-16 $ 37.55 (-0.84%)
2020-11-13 $ 37.87 (-1.69%)
2020-11-12 $ 38.52 (-1.91%)
2020-11-10 $ 39.66 (13.83%)
2020-11-09 $ 34.84 (23.77%)
2020-11-07 $ 28.15 (-4.32%)
2020-11-06 $ 28.15 (-4.32%)
2020-11-02 $ 28.52 (2.63%)
2020-10-29 $ 28.94 (0.63%)
2020-10-24 $ 29.3 (0.17%)
2020-10-22 $ 29.48 (-2.96%)
2020-09-09 $ 44.62 (1.23%)
2020-09-03 $ 45.49 (-1.3%)
2020-08-28 $ 49.3 (1%)
2020-08-27 $ 48.81 (0.62%)
2020-08-21 $ 48.21 (-1.13%)
2020-08-11 $ 52.58 (-0.47%)
2020-08-10 $ 52.83 (8.37%)
2020-08-07 $ 48.75 (3.33%)
2020-08-06 $ 47.18 (-1.79%)
2020-08-05 $ 48.04 (0.97%)
2020-08-03 $ 47.23 (3.48%)
2020-07-29 $ 45.6 (-0.65%)
2020-07-01 $ 46.52 (-2.9%)
2020-06-30 $ 47.91 (2.59%)
2020-06-29 $ 46.7 (-39.73%)
2020-06-18 $ 76.62 (-2.3%)
2020-06-17 $ 78.42 (-0.29%)
2020-06-16 $ 78.65 (1.61%)
2020-06-10 $ 79.61 (-1.33%)
2020-06-09 $ 82.32 (5.65%)
2020-06-03 $ 76.67 (1.71%)
2020-05-27 $ 74.43 (-2.67%)
2020-05-26 $ 76.47 (-5.02%)
2020-05-22 $ 80.51 (-12.19%)
2020-05-12 $ 89.05 (-1.54%)
2020-05-11 $ 90.44 (3.01%)
2020-05-06 $ 88.38 (9.99%)
2020-05-04 $ 78.64 (2.13%)
2020-04-27 $ 86.72 (3.86%)
2020-04-09 $ 69.26 (3.3%)
2020-04-08 $ 67.05 (6.58%)
2020-04-01 $ 58.4 (-7.24%)
2020-03-30 $ 65.03 (-0.06%)
2020-03-26 $ 67.7 (9.18%)
2020-02-28 $ 91.94 (7.67%)
2020-02-18 $ 96.87 (2.14%)
2020-01-29 $ 93.54 (-1.01%)
2020-01-08 $ 117.31 (1.35%)
2019-12-24 $ 124.1 (0.13%)
2019-12-13 $ 114.16 (-1.53%)
2019-12-10 $ 114.88 (3.62%)
2019-12-06 $ 119.78 (1.82%)
2019-12-02 $ 112.3 (3.63%)
2019-11-28 $ 109.16 (7.56%)
2019-11-25 $ 96.34 (8.38%)
2019-11-08 $ 82.76 (2.35%)
2019-10-29 $ 74.5 (0.04%)
2019-10-28 $ 74.47 (1.33%)
2019-09-28 $ 64.12 (0.69%)
2019-09-25 $ 65.26 (-0.53%)
2019-09-11 $ 68.97 (2.1%)
2019-09-09 $ 64.46 (2.74%)
2019-08-23 $ 60.9 (-3.3%)
Total 139
  • 1
  • 2